EyePoint Pharmaceuticals所有资讯

贝雅维持EyePoint Pharmaceuticals(EYPT.US)买入评级，下调目标价至33美元

富途资讯11/11 20:31

JonesTrading维持EyePoint Pharmaceuticals(EYPT.US)买入评级，维持目标价45美元

富途资讯11/11 20:31

H.C. Wainwright维持EyePoint Pharmaceuticals(EYPT.US)买入评级，下调目标价至22美元

富途资讯11/11 20:31

eyepoint pharmaceuticals被HC Wainwright & Co.维持为买入

道琼斯11/11 20:24

eyepoint pharmaceuticals股价目标由HC Wainwright & Co.下调至22.00美元/股，原先为30.00美元。

道琼斯11/11 20:24

Chardan Capital维持对eyepoint pharmaceuticals的买入评级，并将目标股价上调至33美元

Benzinga11/09 06:16

TD Cowen维持EyePoint Pharmaceuticals(EYPT.US)买入评级，下调目标价至20美元

富途资讯11/08 01:30

eyepoint pharmaceuticals：临床试验进展及有望的中期数据推动了买入评级

TipRanks11/08 00:50

丰业银行维持EyePoint Pharmaceuticals(EYPT.US)买入评级，维持目标价18美元

富途资讯10/29 19:34

eyepoint pharmaceuticals被查丹资本维持买入评级

道琼斯10/29 19:11

eyepoint pharmaceuticals 分析师评级

Benzinga10/29 19:00

第一资本维持EyePoint Pharmaceuticals(EYPT.US)买入评级，维持目标价35美元

富途资讯10/28 23:32

JonesTrading首予EyePoint Pharmaceuticals(EYPT.US)买入评级，目标价45美元

富途资讯10/28 22:32

贝雅维持EyePoint Pharmaceuticals(EYPT.US)买入评级，维持目标价38美元

富途资讯10/25 23:34

eyepoint pharmaceuticals的分析师评级

Benzinga10/25 22:02

H.C. Wainwright维持EyePoint Pharmaceuticals(EYPT.US)买入评级，维持目标价30美元

富途资讯10/25 18:31

eyepoint pharmaceuticals积极前景：DURAVYU的第3阶段LUGANO试验推动买入评级提升

TipRanks10/25 18:20

第一资本维持EyePoint Pharmaceuticals(EYPT.US)买入评级，维持目标价35美元

富途资讯10/25 04:32

Scotiabank开始覆盖eyepoint pharmaceuticals，给予板块表现评级，并宣布目标价为18美元。

Benzinga10/16 22:34

瑞穗证券维持EyePoint Pharmaceuticals(EYPT.US)买入评级

富途资讯10/11 16:31